24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Scientists Discover New Way Fat Harms Your ArteriesOpioid Prescriptions for Eye Surgery Patients SurgeCases of Vaping-Linked Lung Illness Rise to 530 Across 38 States: CDCHealth Tip: Gaining WeightCan You Still Be Healthy If You're Overweight?Intense Gaming Can Trigger Irregular Heartbeat, Fainting in Some PlayersAll-in-One Pill Helps Protect HeartTiny Genetic Tweak May Stop Ebola Virus in Its TracksOpioid Epidemic Tied to Doubling of Dangerous Heart InfectionsWill Feeding Your Pets Raw Food Make You Sick?AHA News: Vitamin D Is Good for the Bones, But What About the Heart?Health Tip: Understanding Color BlindnessCould Profit Be a Factor in Kidney Transplant Decisions?Could Daily Low-Dose Aspirin Still Help Some People?Health Tip: Relieving Itchy SkinExperts' Guide to Trampoline SafetyHow to Keep Your Feet on a Sound, Pain-Free FootingMost Cyclists Suffering Head Injuries Not Wearing Helmets: StudyLinks Between Smog, 2nd Pregnancies and Preterm BirthHeartburn Drug Zantac May Contain Small Amounts of Known Carcinogen, FDA SaysCDC Revises Number of Vaping-Linked Lung Illnesses to 380 in 36 StatesKidney Transplants Safe When Donors Had Hepatitis CLung Cancer Screening Can Detect Other Smoking IllsIs Your State One of the 'Most Obese' in America?How to Keep Your Bones Strong and Prevent FracturesHeart Attack Can Be More Lethal If Symptoms Are More GradualHealth Tip: Understanding MononucleosisNew Strain of Strep Causing Cases of Scarlet FeverHow to Fight Hidden Causes of InflammationFDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaOccasional Naps Do a Heart Good, Swiss Study FindsA 'Supercool' Breakthrough for Patients Awaiting Liver TransplantTreatment for Very-Preterm Infants May Lead to Antibiotic ResistanceWhy Weight Gain Often Comes With AgeNew Prosthetic Leg Can Feel Touch, Reduce 'Phantom Limb' PainThe Alexander Technique: What Could It Do for You?Drink Coffee, Avoid Gallstones?Dark Skin No Protection Against Sun's Harmful RaysSome People Vaccinated Against Mumps May Not Be Protected: StudyDiabetes Control Has Stalled Across U.S.Vaping-Linked Lung Illnesses Double, Vitamin E Acetate Leading Suspect'First Responders' on 9/11 Face Lingering Heart Woes, Study FindsHealth Officials Close in on Culprit in Vaping Lung Injury CasesGoing Vegetarian Good for Your Heart, But May Up Stroke RiskEven Small Improvements in Cholesterol, Blood Pressure Help Prevent Heart AttackHealth Tip: Signs of GallstonesHigh Post-Hospital Death Rate Trails Ebola SurvivorsClues to Why Epileptic Seizures Can Halt BreathingWhat Works Best Against Varicose Veins?Poor Circulation in Legs? Statin Meds Can Keep You Living Longer
Questions and AnswersLinks
Related Topics

Diabetes

Drug Approved to Treat Tenosynovial Giant Cell Tumor


HealthDay News
Updated: Aug 5th 2019

new article illustration

MONDAY, Aug. 5, 2019 (HealthDay News) -- Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), the U.S. Food and Drug Administration announced.

The drug was approved for patients with TGCT with severe morbidity or functional limitations that has not improved with surgery. Turalio is only available through the Risk Evaluation and Mitigation Strategy Program.

Approval was based on data from a multicenter international clinical trial of 120 patients. After 25 weeks, patients who received Turalio had a statistically significant improvement in overall response rate (ORR) to an ORR of 38 percent versus no response in patients who received placebo. Fifteen percent of patients had a complete response and 23 percent had a partial response. Among patients followed for a minimum of six months following initial response, 22 of 23 patients maintained their response for six months or longer; all 13 patients who initially responded and were followed for a minimum of 12 months maintained their response for 12 months or longer.

Commonly reported side effects include lactate dehydrogenase, increased aspartate aminotransferase, loss of hair color, increased alanine aminotransferase, and increased cholesterol. Side effects also include neutropenia, increased alkaline phosphatase, decreased lymphocytes, eye edema, decreased hemoglobin, rash, dysgeusia, and decreased phosphate. A Boxed Warning on the prescription information for Turalio warns about the risk for serious and potentially fatal liver injury and advises health care professionals to monitor patients' liver tests before and during treatment and to alter or discontinue use of the drug if liver tests are abnormal.

Approval was granted to Daiichi Sankyo.

More Information